(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/088967 A1

(51) International Patent Classification[7]: A61K 31/4545, C07D 471/04, 401/14, A61K 31/4184, A61P 37/08

(21) International Application Number: PCT/US03/11672

(22) International Filing Date: 16 April 2003 (16.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/373,731 18 April 2002 (18.04.2002) US

(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(72) Inventors: ZENG, Qingbei; 509 Cider Road, Edison, NJ 08820 (US). ASLANIAN, Robert, G.; 144 Philip Drive, Rockaway, NJ 07866 (US). BERLIN, Michael, Y.; 14 Hendrick Road, Flemington, NJ 08822 (US). BOYCE, Christopher, W.; 71 Bonnell Street, Flemington, NJ 08822 (US). CAO, Jianhua; 203 Country Club Lane, Scotch Plains, NJ 07076 (US). KOZLOWSKI, Joseph, A.; P. O. Box 7391, Princeton, NJ 08543 (US). MANGIARACINA, Pietro; 4 Montclair Avenue, Monsey, NY 10952 (US). MC CORMICK, Kevin, D.; 5 Pace Drive, Edison, NJ 08820 (US). MUTAHI, Mwangi, W.; 532 Berkeley Avenue, Orange, NJ 07050 (US). ROSENBLUM, Stuart, B.; 16 Steven Terrace, West Orange, NJ 07052 (US). SHIH, Neng-Yang; 1 Maple Drive, North Caldwell, NJ 07006 (US). SOLOMON, Daniel, M.; 9 Marshall Drive, Edison, NJ 08817 (US). TOM, Wing, C.; 133 Cedar Grove Parkway, Cedar Grove, NJ 07009 (US).

(74) Agent: MAGATTI, Anita, W.; Schering-Plough Corporation, Patent Department -K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/088967 A1

(54) Title: (1-4-PIPERIDINYL) BENZIMIDAZOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS



(I)

(57) Abstract: Disclosed are histamine H_3 antagonists of the formula (I) wherein R^1 is optionally substituted benzimidazolyl or a derivative thereof; R^2 is optionally substitutd aryl or heteroaryl; M_1 and M^2 are $C(R^3)$ or N; Q is $-N(R^8)-$, -S- or -O-; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I. Also disclosed are methods of treating said diseases or conditions using the compounds of formula I in combination with an H_1 receptor antagonist.